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benzohydrazides as potential anticancer agents†
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Khyati D. Bhatelia,b Kavya Ananthaswamy,b Sureshbabu A. Ramareddy,a Erik De
Clercq,d Bibha Choudhary,e Dominique Schols,d Sathees C. Raghavanb
and Subhas S. Karki*a
New N0-[2-oxo-1,2-dihydro-3H-indol-3-ylidene]benzohydrazide derivatives were synthesized and
evaluated for their cytotoxic properties against murine leukemia, L1210, human leukemia, REH and K562,
human T-cell leukemia, CEM and human cervix carcinoma, HeLa cells. Among the tested compounds,
the 3,4,5-trimethoxy-N0-[5-methyl-2-oxo-1,2-dihydro-3H-indol-3-ylidene]benzohydrazide derivative
(5t) emerged as the most potent inhibitor against all the tumor cell lines evaluated. To investigate the
mechanism of action, 5t was further studied by cell cycle analysis, mitochondrial membrane potential
analysis, DNA fragmentation and Annexin V-FITC ﬂow cytometric analysis, which suggested that 5t
was able to induce apoptosis at submicromolar range.1. Introduction
Cancer is the most wide-spread disease across the world today.
Chemotherapy is one of the main methods used for cancer
treatment. The majority of drugs currently used for the treat-
ment of cancer are cytotoxic, targeting various pathways in the
cell, for example DNA repair pathways.1–4 Most of the cytotoxic
drugs which are under clinical trial are of potent activity with
submicromolar range. Therefore, it will be of great importance
to design and develop new compounds with lower IC50 values.
Various compounds having general formula 1 display anti-
cancer activities.5 Hydrazide derivatives possess an interesting
biological activity such as anti-platelet,6 analgesic,7,8 antimi-
crobial,9 anti-inammatory,10 and anticancer 211 activities.
Various acyclic thiosemicarbazones 3 are lethal to mice at doses
of 25–100 mg kg1.12 The isatin-based hydrazones were reported
as antioxidants,13 commercial herbicides and acetohydroxy acid
synthase inhibitors,14 and beta-secretase-1 (BACE1) inhibitors.15KLE University's College of Pharmacy,
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tion (ESI) available. See DOI:
01The hydrazide (–CH]N–NH–CO–) moiety has an important role
as part of antitumor agents 2.16–18
Previously, we have reported isatin-based thiosemicarbazide
derivatives as cytotoxic agents 4.19 The objectives of the present
investigation were to develop analogs of 3 and 4 as potent
cytotoxic agents. The derivatives 3 and 4 display cytotoxicity to
human CEM T-lymphocytes and their IC50 values were high, viz,
83 000 and 2300 nM, respectively. The derivative 4 was more
potent, because of insertion of polar atoms like carbonyl in
place of the methylene functional group. From this basic
design, we inserted an oxygen atom instead of sulfur as in
isatin-hydrazones 5 and evaluated their cytotoxicity in human
and murine tumor cell lines (Fig. 1). Moreover the possible
underlying mechanism of action (MOA) has also been
investigated.2. Experimental
2.1. Chemicals and reagents
The melting points are uncorrected. The IR spectra were recorded
in KBr on a Jasco 430+; the 1H NMR spectra were recorded in
CDCl3/DMSO on a Bruker (400 MHz), and J values were reported
in hertz (Hz). Mass spectra were recorded in triple quadrapole
LCMS-6410 from Agilent technologies. 5-Cl-isatin,20 5-F-isatin,21 5-
CH3-isatin,22 5-NO2-isatin,23 4-Cl-phenyl hydrazide,24 4-Br-phenyl
hydrazide,25 4-NO2-phenyl hydrazide,26 4-OCH3-phenyl hydra-
zide27 and 3,4,5-tri-OCH3-phenyl hydrazide28 were prepared
according to the literature. 4-Bromo-N0-[2-oxo-1,2-dihydro-3H-
indol-3-ylidene]benzohydrazide (5b) 4-nitro-N0-[2-oxo-1,2-dihydro-
3H-indol-3-ylidene]benzohydrazide (5c) and N0-[5-nitro-2-oxo-1,2-This journal is © The Royal Society of Chemistry 2015
Fig. 1 Structures of various thiosemicarbazones and hydrazides.
Paper RSC Advancesdihydro-3H-indol-3-ylidene]benzohydrazide (5x) were prepared
according to the literature.29 While compounds N0-[5-chloro-
2-oxo-1,2-dihydro-3H-indol-3-ylidene]-4-methoxybenzo-hydrazide
(5i) and N0-[5-uoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene]benzo-
hydrazide (5n) were prepared according to literature.302.2. General procedure for the synthesis of the N0-[2-oxo-1,2-
dihydro-3H-indol-3-ylidene]benzohydrazide (5a–y)
A mixture of the 1H-indole-2,3-dione (I, 0.005 mol), aryl hydra-
zone (II, 0.007 mol) and ethanol (100 ml) was heated under
reux until the reaction was completed (4 h). Approximately
half of the ethanol was removed in vacuo and the solution was
le overnight at room temperature. The solid which precipi-
tated was collected, washed with cold ethanol and recrystallized
from ethanol : chloroform (9 : 1) to give the following
compounds.
2.2.1. 4-Chloro-N0-[2-oxo-1,2-dihydro-3H-indol-3-ylidene]-
benzohydrazide (5a). Obtained according to the general proce-
dure for the synthesis of the N0-[2-oxo-1,2-dihydro-3H-indol-3-
ylidene]benzohydrazide-yield 75%, MP > 300 C; molecular
formula C15H10ClN3O2, molecular weight 299.71, IR: 3218, 3163,
3052, 3009, 2918, 2845, 1692, 1670, 1586, 1593, 1539, 1480, 1414,
1379, 1309, 1271, 1164. 1H NMR: 13.85 (1H, s, NH), 11.41 (1H, s,
NH), 7.92–7.89 (3H, dm, J¼ 8), 7.71 (2H, d, J¼ 8), 7.44–7.41 (1H,
m, ar), 7.27–7.22 (1H, m, ar), 6.98–6.94 (1H, m, ar).
2.2.2. 4-Methoxy-N0-[2-oxo-1,2-dihydro-3H-indol-3-ylidene]-
benzohydrazide (5d). Obtained according to the general proce-
dure for the synthesis of the N0-[2-oxo-1,2-dihydro-3H-indol-3-
ylidene]benzohydrazide-yield 74%, MP 268–270 C; molecular
formula C16H13N3O3, molecular weight 295.29, IR: 3289, 3165,
3065, 2936, 2833, 1692, 1586, 1523, 1492, 1414, 1330, 1263,
1127. NMR: 13.87 (1H, s, NH), 11.33 (1H, s, NH), 7.88 (2H, d, J¼This journal is © The Royal Society of Chemistry 20158), 7.60 (1H, d, J ¼ 8), 7.38 (1H, t, J ¼ 16), 7.15–7.09 (3H, dm, J ¼
8), 6.96 (1H, d, J ¼ 8).
2.2.3. 3,4,5-Trimethoxy-N0-[2-oxo-1,2-dihydro-3H-indol-3-
ylidene]benzohydrazide (5e). Obtained according to the
general procedure for the synthesis of the N0-[2-oxo-1,2-dihy-
dro-3H-indol-3-ylidene]benzohydrazide-yield 77%, MP 276–
278 C; molecular formula C18H17N3O5, molecular weight
355.34, IR: 3268, 3199, 3065, 2942, 2836, 1677, 1589, 1539,
1499, 1465, 1333. NMR: 13.91 (1H, s, NH), 11.31 (1H, s, NH),
7.62 (1H, d, J¼ 8), 7.40 (1H, t, J¼ 16), 7.19 (2H, s, ar), 7.12 (1H,
t, J ¼ 16), 6.98 (1H, d, J ¼ 8), 3.87 (6H, s, 2-OCH3), 3.76 (3H, s,
OCH3). MS (ESI) m/z: 354.00 (355.34).
2.2.4. 4-Chloro-N0-[5-chloro-2-oxo-1,2-dihydro-3H-indol-3-
ylidene]benzohydrazide (5f). Obtained according to the general
procedure for the synthesis of the N0-[2-oxo-1,2-dihydro-3H-
indol-3-ylidene]benzohydrazide-yield 74%, MP > 300 C; molec-
ular formula C15H9Cl2N3O2, molecular weight 334.15, IR:
3231, 3187, 3047, 2917, 2849, 1686, 1593, 1461, 1262, 1147.
NMR: 13.81 (1H, s, NH), 11.49 (1H, s, NH), 7.92 (2H, d, J ¼ 8),
7.71 (2H, d, J ¼ 8), 7.59 (1H, s, ar), 7.45–7.43 (1H, m, ar.), 6.99
(1H, d, J ¼ 8). MS (ESI) m/z: 332.00 (334.15).
2.2.5. 4-Bromo-N0-[5-chloro-2-oxo-1,2-dihydro-3H-indol-3-
ylidene]benzohydrazide (5g). Obtained according to the
general procedure for the synthesis of the N0-[2-oxo-1,2-dihy-
dro-3H-indol-3-ylidene]benzohydrazide-yield 75%, MP 288–
290 C; molecular formula C15H9BrClN3O2, molecular weight
378.60, IR: 3228, 3047, 2918, 2851, 1686, 1592, 1531, 1462,
1308, 1261, 1146. NMR: 13.81 (1H, s, NH.), 11.48 (1H, s, NH),
7.86–7.81 (4H, m, ar), 7.59 (1H, s, ar), 7.56 (1H, s, ar), 7.45–7.43
(1H, m, ar), 6.99 (2H, d, J ¼ 8). MS (ESI) m/z: 380.00 (378.60).
2.2.6. N0-[5-Chloro-2-oxo-1,2-dihydro-3H-indol-3-ylidene]-4-
nitrobenzohydrazide (5h). Obtained according to the general
procedure for the synthesis of the N0-[2-oxo-1,2-dihydro-3H-RSC Adv., 2015, 5, 45492–45501 | 45493
RSC Advances Paperindol-3-ylidene]benzohydrazide-yield 72%, MP > 300 C;
molecular formula C15H9ClN4O4, molecular weight 344.70, IR:
3247, 3175, 2917, 2849, 1708, 1681, 1601, 1525, 1462, 1352,
1316. NMR: 13.93 (1H, s, NH), 11.57 (1H, s, NH), 8.42 (2H, d, J¼
8), 8.14 (3H, dm, J¼ 8), 7.46–7.43 (1H, m, ar), 6.99 (1H, d, J¼ 8).
MS (ESI) m/z: 343.00 (344.70).
2.2.7. N0-[5-Chloro-2-oxo-1,2-dihydro-3H-indol-3-ylidene]-
3,4,5-trimethoxy-benzohydrazide (5j). Obtained according to
the general procedure for the synthesis of the N0-[2-oxo-1,2-
dihydro-3H-indol-3-ylidene]benzohydrazide-yield 67%, MP >
300 C; molecular formula C18H16ClN3O5, molecular weight
389.78, IR: 3265, 3108, 3047, 2942, 2835, 1710, 1661, 1580, 1527,
1492, 1333. NMR: 13.87 (1H, s, NH), 11.42 (1H, s, NH), 7.61 (1H,
s, ar), 7.45–7.42 (1H, m, ar), 7.19 (2H, s, ar), 7.00 (1H, d, J ¼ 8),
3.87 (6H, s, 2-OCH3), 3.76 (3H, s, OCH3). MS (ESI) m/z: 390.10
(389.78).
2.2.8. 4-Chloro-N0-[5-uoro-2-oxo-1,2-dihydro-3H-indol-3-
ylidene]benzohydrazide (5k). Obtained according to the general
procedure for the synthesis of the N0-[2-oxo-1,2-dihydro-3H-
indol-3-ylidene]benzohydrazide-yield 75%, MP > 300 C;
molecular formula C15H9ClFN3O2, molecular weight 317.70, IR:
3219, 3055, 2922, 2850, 1715, 1671, 1594, 1540, 1480, 1309,
1271, 1164. NMR: 13.87 (1H, s, NH.), 11.39 (1H, s, NH), 7.92 (2H,
d, J¼ 8), 7.71 (2H, d, J¼ 8), 7.43 (1H, s, ar), 7.27–7.22 (1H, m, ar),
6.98–6.95 (1H, m, ar). MS (ESI) m/z: 316.10 (317.70).
2.2.9. 4-Bromo-N0-[5-uoro-2-oxo-1,2-dihydro-3H-indol-3-
ylidene]benzohydrazide (5l). Obtained according to the general
procedure for the synthesis of the N0-[2-oxo-1,2-dihydro-3H-
indol-3-ylidene]benzohydrazide-yield 75%, MP > 300 C;
molecular formula C15H9BrN3O2, molecular weight 362.15, IR:
3216, 3062, 2925, 2850, 1720, 1669, 1590, 1539, 1479, 1390,
1270, 1162. NMR: 13.87 (1H, s, NH.), 11.39 (1H, s, NH), 7.83 (4H,
s, ar), 7.44–7.42 (1H, m, ar), 7.27–7.22 (1H, m, ar), 6.98–6.95 (1H,
m, ar). MS (ESI) m/z: 362.00 (362.15).
2.2.10. N0-[5-Fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene]-
4-nitrobenzohydrazide (5m). Obtained according to the general
procedure for the synthesis of the N0-[2-oxo-1,2-dihydro-3H-
indol-3-ylidene]benzohydrazide-yield 76%, MP > 300 C;
molecular formula C15H9FN4O4, molecular weight 328.25, IR:
3222, 3059, 2918, 2849, 1674, 1599, 1519, 1479, 1275. NMR:
13.91 (1H, s, NH), 11.41 (1H, s, NH), 8.44 (2H, d, J¼ 8), 8.14 (2H,
d, J¼ 8), 7.45 (1H, s, ar), 7.28–7.23 (1H, m, ar), 6.98–6.95 (1H, m,
ar). MS (ESI) m/z: 327.10 (328.25).
2.2.11. N0-[5-Fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene]-
3,4,5-trimethoxybenzohydrazide (5o). Obtained according to
the general procedure for the synthesis of the N0-[2-oxo-1,2-
dihydro-3H-indol-3-ylidene]benzohydrazide-yield 71%, MP 228–
230 C; molecular formula C18H16FN3O5, molecular weight
373.33, IR: 3229, 3065, 2949, 1674, 1587, 1532, 1482, 1332, 1129.
NMR: 13.95 (1H, s, NH), 11.35 (1H, s, NH), 7.48–7.45 (1H, m, ar),
7.29–7.23 (1H, m, ar), 7.22 (2H, s, ar), 7.01–6.98 (1H, s, ar), 3.89
(6H, s, 2-OCH3), 3.78 (3H, s, OCH3). MS (ESI) m/z: 374.33
(373.33).
2.2.12. 4-Chloro-N0-[5-methyl-2-oxo-1,2-dihydro-3H-indol-
3-ylidene]benzohydrazide (5p). Obtained according to the
general procedure for the synthesis of the N0-[2-oxo-1,2-dihydro-
3H-indol-3-ylidene]benzohydrazide-yield 75%, MP > 300 C;45494 | RSC Adv., 2015, 5, 45492–45501molecular formula C16H12ClN3O2, molecular weight 313.73, IR:
3230, 3040, 2919, 2851, 1709, 1671, 1599, 1482, 1378, 1273,
1140. NMR: 13.90 (1H, s, NH), 11.26 (1H, s, NH), 7.91 (2H, d, J¼
8), 7.70 (2H, d, J¼ 8), 7.43 (1H, s, ar), 7.22 (1H, d, J¼ 8) 6.86 (1H,
d, J ¼ 8), 2.31 (3H, s, CH3). MS (ESI) m/z: 314.10 (313.73).
2.2.13. 4-Bromo-N0-[5-methyl-2-oxo-1,2-dihydro-3H-indol-
3-ylidene]benzohydrazide (5q). Obtained according to the
general procedure for the synthesis of the N0-[2-oxo-1,2-dihydro-
3H-indol-3-ylidene]benzohydrazide-yield 77%, MP > 300 C;
molecular formula C16H12BrN3O2, molecular weight 358.18, IR:
3232, 3040, 2919, 2851, 1708, 1671, 1594, 1525, 1481, 1378,
1273. NMR: 13.88 (1H, s, NH), 11.25 (1H, s, NH), 7.82 (4H, m,
ar), 7.42 (1H, s, ar), 7.21 (1H, d, J ¼ 8), 6.85 (1H, d, J ¼ 8), 2.30
(3H, s, CH3). MS (ESI) m/z: 358.00 (358.18).
2.2.14. N0-[5-methyl-2-oxo-1,2-dihydro-3H-indol-3-ylidene]-
4-nitrobenzohydrazide (5r). Obtained according to the general
procedure for the synthesis of the N0-[2-oxo-1,2-dihydro-3H-
indol-3-ylidene]benzohydrazide-yield 74%, MP > 300 C;
molecular formula C16H12N4O4, molecular weight 324.29, IR:
3256, 3113, 2918, 2851, 1702, 1677, 1601, 1523, 1339, 1140.
NMR: 14.01 (1H, s, NH), 11.31 (1H, s, NH), 8.45 (2H, d, J ¼ 8),
8.13 (2H, d, J¼ 8), 7.43 (1H, s, br), 7.23 (1H, d, J¼ 8), 6.87 (1H, d,
J ¼ 8), 2.31 (3H, s, CH3). MS (ESI) m/z: 323.10 (324.29).
2.2.15. N0-[5-methyl-2-oxo-1,2-dihydro-3H-indol-3-ylidene]-
benzohydrazide (5s). Obtained according to the general proce-
dure for the synthesis of the N0-[2-oxo-1,2-dihydro-3H-indol-3-
ylidene]benzohydrazide-yield 71%, MP > 300 C; molecular
formula C16H13N3O2, molecular weight 279.29, IR: 3232, 3036,
2915, 2848, 1703, 1673, 1594, 1522, 1481, 1382, 1139. NMR:
13.81 (1H, s, NH), 11.25 (1H, s, NH), 7.84–7.79 (5H, m, ar), 7.42
(1H, s, ar), 7.21 (1H, d, J¼ 8) 6.86 (1H, d, J¼ 8), 2.30 (3H, s, CH3).
2.2.16. 3,4,5-Trimethoxy-N0-[5-methyl-2-oxo-1,2-dihydro-
3H-indol-3-ylidene]-benzohydrazide (5t). Obtained according to
the general procedure for the synthesis of the N0-[2-oxo-1,2-dihy-
dro-3H-indol-3-ylidene]benzohydrazide-yield 74%, MP 150 C;
molecular formula C19H19N3O5, molecular weight 369.37, IR:
3502, 3137, 3097, 2919, 1675, 1564, 1357, 1154. NMR: 13.92 (1H,
s, NH.), 11.20 (1H, s, NH), 7.45 (1H, s, ar), 7.21–7.18 (3H, m, ar),
6.87 (1H, d, J ¼ 8), 3.86 (6H, s, 2-OCH3), 3.76 (3H, s, OCH3), 2.31
(3H, s, CH3). MS (ESI) m/z: 368.10 (369.37).
2.2.17. 4-Chloro-N0-[5-nitro-2-oxo-1,2-dihydro-3H-indol-3-
ylidene]benzohydrazide (5u). Obtained according to the general
procedure for the synthesis of the N0-[2-oxo-1,2-dihydro-3H-indol-
3-ylidene]benzohydrazide-yield 76%, MP > 300 C; molecular
formula C15H9ClN4O4, molecular weight 344.70, IR: 3176, 3108,
2918, 2849, 1706, 1676, 1601, 1528, 1467. NMR: 13.69 (1H, s, NH.),
12.03 (1H, s, NH), 8.34–8.29 (2H, m, ar), 7.94 (2H, d, J ¼ 8), 7.74
(2H, d, J ¼ 8), 7.18 (1H, d, J ¼ 8). MS (ESI) m/z: 343.00 (344.70).
2.2.18. 4-Bromo-N0-[5-nitro-2-oxo-1,2-dihydro-3H-indol-3-
ylidene]benzohydrazide (5v). Obtained according to the general
procedure for the synthesis of the N0-[2-oxo-1,2-dihydro-3H-
indol-3-ylidene]benzohydrazide-yield 71%, MP > 300 C;
molecular formula C15H9BrN4O4, molecular weight 389.16, IR:
3176, 3108, 2845, 1706, 1674, 1593, 1528, 1466, 1340, 1217.
NMR: 13.69 (1H, s, NH.), 12.03 (1H, s, NH), 8.34–8.29 (2H, m,
ar), 7.89–7.84 (4H, m, ar), 7.19 (1H, d, J ¼ 8). MS (ESI) m/z:
388.90 (389.16).This journal is © The Royal Society of Chemistry 2015
Paper RSC Advances2.2.19. 4-Nitro-N0-[5-nitro-2-oxo-1,2-dihydro-3H-indol-3-
ylidene]benzohydrazide (5w). Obtained according to the general
procedure for the synthesis of the N0-[2-oxo-1,2-dihydro-3H-
indol-3-ylidene]benzohydrazide-yield 75%, MP > 300 C;
molecular formula C15H9N5O6, molecular weight 355.26, IR:
3192, 3108, 2925, 1707, 1681, 1603, 1523, 1343, 1146. NMR:
13.68 (1H, s, NH), 12.02 (1H, s, NH), 8.46 (2H, d, J¼ 8), 8.34–8.31
(2H, m, ar), 8.29 (1H, s, ar), 8.16 (2H, d, J¼ 8), 7.19 (1H, d, J¼ 8).
MS (ESI) m/z: 354.10 (355.26).
2.2.20. 3,4,5-Trimethoxy-N0-[5-nitro-2-oxo-1,2-dihydro-3H-
indol-3-ylidene]-benzohydrazide (5y). Obtained according to the
general procedure for the synthesis of the N0-[2-oxo-1,2-dihydro-
3H-indol-3-ylidene]benzohydrazide-yield 70%, MP 298–300 C;
molecular formula C18H16N4O7, molecular weight 400.34, IR:
3144, 3089, 2949, 2918, 1702, 1662, 1585, 1336, 1132. NMR:
13.70 (1H, s, NH.), 11.92 (1H, s, NH), 8.32–8.30 (2H, m, ar), 7.22–
7.17 (3H, m, ar), 3.88 (6H, s, 2-OCH3), 3.77 (3H, s, OCH3). MS
(ESI) m/z: 399.10 (400.34).
2.3. Biological evaluations
2.3.1. Cell cultures. Human cell lines K562 (chronic
myelogenous leukemia), REH (B-cell leukemia) were cultured in
RPMI1640 (Sera Lab, UK) containing 10% FBS (Gibco BRL, USA)
along with 100 U of penicillin G per ml as well as 100 mg of
streptomycin per ml (Sigma-Aldrich, USA) at 37 C in a
humidied atmosphere containing 5% CO2.
2.3.2. Cytostatic assays. The methodology for undertaking
the antiproliferative assays has been published previously.31 In
brief, varying concentrations of the compounds (5-fold dilu-
tions) were incubated at 37 C for 72 h (HeLa and CEM T-
lymphocytes) or 48 h (L1210 cells) in 200 ml 96-well microtiterScheme 1 Synthesis of N0-[2-oxo-1,2-dihydro-3H-indol-3-ylidene]benz
This journal is © The Royal Society of Chemistry 2015plates, and the viable tumor cell number was counted at the end
of the incubation period using a Coulter Counter (Coulter
Electronics, Harpenden Hertz, U.K.).
2.3.3. Trypan blue dye exclusion assay. The viability of the
leukemic cells (REH, K562) were determined by trypan blue dye
exclusion assay aer treatment with 5t.32 Cells were cultured
(0.5  105 cells per ml) for 24 h and 5t was added at diﬀerent
concentration (0–10 mM). DMSO treated cells were used as
vehicle control. Cells were collected at 48 and 72 h aer treat-
ment with 5t and viable cells were counted following trypan
blue staining. Each experiment was repeated three independent
times and standard error mean was calculated and plotted with
error bars.
2.3.4. MTT assay. The proliferation rate of the cells aer
treatment with 5t was checked by using MTT assay.33 REH, K562
cells (0.5  105 cells per ml) were treated with 5t and MTT assay
was carried out aer 48 and 72 h incubation. Cells treated with
equal amount of DMSO were used as vehicle control. Experi-
ment was repeated three independent times each with duplicate
reactions and bar diagram was plotted with error bars.
2.3.5. Cell cycle analysis. Eﬀect of 5t on cell cycle was
checked as described previously.34 Briey, REH cells were
cultured (0.5 105 cells per ml), and aer 24 h incubation, 5twas
added (0, 0.1 and 0.5 mM), cells were harvested aer 24 and 48 h
of treatment, washed, xed with 70% ethanol and RNase-A
treatment was given overnight, nally analyzed in BD
FACSVerse™ ow cytometer using propidium iodide stain. A
minimum of 10 000 cells were acquired per sample and histo-
grams were plotted and analyzed using owing soware (version
2.5). Experiment was repeated two independent times and each
cell cycle phase was indicated in bar diagram with error bar.ohydrazide derivatives (5a–y).
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Table 1 Inhibitory eﬀects of derivatives ofN0-[2-oxo-1,2-dihydro-3H-
indol-3-ylidene]benzohydrazide derivatives (5a–y) on the proliferation
of murine leukemia (L1210), human T-lymphocyte (CEM) and cervix
carcinoma (HeLa) cells
Code
IC50
a (mM)
L1210 CEM HeLa
5a >250 >250 >250
5b >250 >250 >250
5c >250 >250 >250
5d 31  21 10  5 22  4
5e 35  29 6.7  0.9 59  11
5f >250 >250 >250
5g 70  35 31  7 19  2
5h >250 >250 >250
5i >250 >250 >250
5j >250 >250 >250
5k >250 >250 >250
5l >250 >250 >250
5m >250 >250 >250
5n >250 >250 >250
5o >250 >250 >250
5p 190  11 114  1 130  13
5q 33  2 16  8 23  4
5r >250 >250 >250
5s 18  4 6.3  0.9 22  0
5t 0.90  0.06 0.66  0.23 1.0  0.2
5u 147  10 138  22 100  40
5v >250 >250 >250
5w >250 >250 >250
5x 138  11 131  8 125  16
5y 130  2 >250 >250
Melphalan 2.13  0.02 1.4  0.4 NT
RSC Advances Paper2.3.6. Measurement of the mitochondrial membrane
potential. Mitochondrial transmembrane potential was
measured using JC-1 (5, 50, 6, 60-tetrachloro-1, 1, 3, 30-tetrae-
thylbenzimidazolcarbocyanamide iodide; Calbiochem, USA) dye
aer treatment with 5t. Briey, aer 48 h of treatment with 5t at
0, 0.1 and 0.5 mM concentration, cells were harvested, and incu-
bated in the media containing 0.5 mM JC-1 for 20 min at 37 C,
cells were washed in phosphate buﬀered saline and analyzed in
(FACS Calibur, BD Biosciences, USA) ow cytometer. 2,4-DNPwas
used as a positive control.35Green (lowmitochondrial membrane
potential) versus red (high mitochondrial membrane potential)
ratio of JC-1 orescence was calculated using owing soware
(version2.5) and represented in a bar diagram with error bar
using two independent experiments.
2.3.7. Annexin V-FITC ow cytometric analysis. Movement
of phosphatidylserine to outer membrane upon apoptotic
induction was detected by Annexin V-FITC staining (Santacruz,
USA).36 REH cells were treated with 5t (0, 0.1 and 0.5 mM) for 48
h and DMSO treated cells were used as vehicle control, cells
were harvested, washed with cold 1 phosphate buﬀered saline
and re-suspended in binding buﬀer (HEPES-10 mM pH 7.4, 144
mMNaCl and 25 mM CaCl2), cells were incubated with Annexin
V-FITC (200 mg per ml) and propidium iodide (10 mg per ml) for
20 min at room temperature and analyzed in BD FACSVerse™
ow cytometer. A minimum of 10 000 cells were acquired per
sample and represented in dot plot. Experiment was repeated
two independent times and bar diagram was plotted for early
apoptosis, late apoptosis and necrosis with error bars.
2.3.8. DNA fragmentation assay. The fragmentation of DNA
aer treatment with 5t was checked using agarose gel electro-
phoresis.37,38 Briey, REH cells were treated with 5t in diﬀerent
concentration (0, 0.1, 0.5 and 1 mM) for 48 h, DMSO treated cells
were used as a vehicle control. Cells were harvested and total
genomic DNAwas isolated using standard protocol, and dissolved
in 1X TE, loaded on 2% agarose gel and run at 50 v for 3 h. DNA
marker was used to check the length of fragmented DNA ladder.
2.3.9. Detection of intracellular ROS production by ow
cytometer. The total intracellular ROS production aer treat-
ment with 5t was determined using cell permeable uorescent
probe 2, 7-dichlorodihydro uorescein diacetate (H2DCFDA) in
REH cells.39 Briey, REH cells were treated with 0.5 mM of 5t for
diﬀerent time points (5, 15, 30 and 60 min), cells were har-
vested, washed with 1 phosphate buﬀered saline and incu-
bated with 0.5 mM H2DCFDA for 37 C for 15 minutes and the
green uorescence intensity was analyzed by ow cytometry
(FACS Calibur, BD Biosciences, USA). Cells which are treated
with H2O2 were used as positive control. The shi in the peak
aer treatment with 5t was compared with control and
percentage of ROS production was determined.
2.3.10. Statistical analysis. The values were expressed as
mean  SEM for control and experimental samples and statis-
tical analysis was performed using one-way ANOVA followed by
the Dunnett test. Signicance was mentioned aer comparing
treated samples with control. For this analysis, GraphPad so-
ware prism 5.1 was used. The values were considered as statis-
tically signicant, if the p-value was equal to or less than 0.05.45496 | RSC Adv., 2015, 5, 45492–455013. Results and discussion
3.1. Chemistry
The synthesis of the N0-[2-oxo-1,2-dihydro-3H-indol-3-ylidene]
benzohydrazide derivatives (5a–y) from 1H-indole-2,3-dione I
and the benzohydrazide II has been outlined in Scheme 1. The
chemical structures of the newly synthesized 5a–y were estab-
lished on the basis of analytical and spectroscopic data. In the
IR spectra, the absorption for carbonyl groups and NH bands
were observed in the range of 1720–1661 cm1 and 3289–3165
cm1, respectively. In the 1H-NMR spectra, the chemical shis
showed for ring NH between d ¼ 13.95–13.66 ppm and for
amide NH between 12.02–11.19 ppm in the form of singlet. The
aromatic protons signals appeared in the range of d¼ 8.46–6.85
ppm. The signals for CH3 and OCH3 were observed in the range
of d ¼ 2.31–2.30 and 3.89–3.76 ppm, respectively. Furthermore,
all compounds were conrmed by ESI-MS and were in agree-
ment with their molecular weight.
3.2. Biological evaluation
3.2.1. Cytotoxicity in human and murine tumor cell
cultures. The evaluation of the compounds in Scheme 1 towards
human cervix carcinoma (HeLa), T-lymphocyte (CEM) and
murine leukemia (L1210) cells was undertaken in order toa 50% inhibitory concentration. NT-not tested.
This journal is © The Royal Society of Chemistry 2015
Paper RSC Advancesdetermine whether the compounds were cytotoxic to human
cancer cells.
The cytotoxicity of the compounds in series 5a–y was deter-
mined and melphalan was used as a standard compound
(Table 1). There was no improvement in cytotoxic activity of
compounds 5a–c, 5f–p and 5u–y. Their IC50 values were >250
mM, except for derivative 5g. When hydrogen was substituted
with electron-withdrawing groups like halogen (Cl/F) and nitro
(NO2) at the 5
th position of the isatin moiety resulting in the
formation of compounds 5f–o and 5u–y, the cytotoxic activity
was poor towards all cell lines. These studies suggest that
electron-withdrawing substitution is not favorable for either the
isatin or the phenyl groups.
However, when the methyl and methoxy groups were
substituted on the isatin and phenyl groups, respectively,
resulting in the formation of the derivatives 5p–t, there was
much improvement in cytotoxicity towards all three cell lines
(IC50 33–0.66 mM) except for compound 5r (IC50 > 250 mM). The
structure–activity relationship study suggests that electron-
donating groups such as methyl and methoxy (5d, 5e, 5q, 5s
and 5t) are preferred over electron-withdrawing substituents
such as halogens (5f–o) and the nitro (5u–y) group. Among the
tested compounds, 5t was clearly the more potent in the
L1210, CEM and HeLa tumor cell assays [sub micromolar
range].
The data therefore provided ample evidence for pursuing
derivative 5t for further study. As the lead compound 5t showed
signicant cytotoxicity against leukemic cells, we further carriedFig. 2 Cytotoxic eﬀect of 5t on REH and K562 cells. REH and K562 cells w
h. Trypan blue assay (to detect the number of viable cells) andMTT assay (
A. Trypan blue assay for 5t treated REH cells. B. MTT assay for 5t treated R
5t treated K562 cells. The cells treated with equal concentration of DMSO
experiment was performed three independent times and error bars are
This journal is © The Royal Society of Chemistry 2015out the studies to understand the mechanism of action in
diﬀerent leukemia cells, namely REH and K562.
3.2.2. Induction of cytotoxicity in REH and K562 cells. To
evaluate the cytotoxicity exerted by 5t, we used the leukemic cell
lines, REH and K562. B-cell leukemia cells (REH) showed a very
good response towards treatment of 5t and we found that the
IC50 value was around 0.5 mM (Fig. 2A and B). At the same time,
chronic myelogenous leukemia cells (K562) showed a moderate
response to 5t and the IC50 value was found to be2 mM (Fig. 2C
and D).
3.2.3. Eﬀect of 5t on cell cycle progression. To check
whether 5t aﬀects cell cycle progression, REH cells were treated
with 5t at diﬀerent concentrations (0, 0.1 and 0.5 mM) for 24 and
48 h. The cells were harvested and analyzed by ow cytometry
aer staining with propidium iodide. The results showed no cell
cycle arrest at tested concentration and time point, however,
signicant accumulation of cells in the SubG1 phase was
observed in a concentration dependent manner (Fig. 3A and B).
3.2.4. Eﬀect of 5t on the mitochondrial membrane poten-
tial.Mitochondria play a major role in induction of apoptosis.40
To check the mitochondrial membrane potential which is very
important for maintaining the integrity of the cell, we treated
REH cells with 5t (100 and 500 nM for 48 h), stained with the JC1
dye and analyzed the cells by FACS. Interestingly, we observed
disruption of the mitochondrial membrane potential in a
concentration dependent manner, which suggests that 5t
induced apoptosis by disruption of the mitochondrial
membrane potential (Fig. 4A and B).ere seeded (0.5 105 cells per ml) and 5t (0–10 mM) was added after 24
to check proliferation rate) were performed at 48 and 72 h of treatment.
EH cells. C. Trypan blue assay for 5t treated K562 cells. D. MTT assay for
was used as vehicle control and in all the cases (indicated by ‘C’). Each
indicated.
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Fig. 3 Cell cycle analysis of 5t treated REH cells. REH cells were seeded (0.5  105 cells per ml) and were treated with 5t (0, 0.1 and 0.5 mM) after
24 h. Cells were harvested after 24 and 48 h of treatment, ﬁxed in 70% ethanol, washed and stained with propidium iodide and analyzed in ﬂow
cytometer. A and B. Histogram representing eﬀect on REH cell cycle by 5t at 24 and 48 h respectively. C and D. The bar graph representing
diﬀerent phases of cell cycle in REH cells after treatment with 5t at 24 and 48 h respectively. Error bars were plotted from two independent
experiments.
RSC Advances Paper3.2.5. Annexin-V-FITC ow cytometry. To check the nature
of cell death, annexin-V-FITC staining was done for REH cells
aer treatment with 0.1 and 0.5 mM of 5t at the 48 h time-point.
Results showed an increased number of annexin-V-FITC-
positive cells aer treatment with 5t, which clearly suggested
the apoptotic mode of cell death (Fig. 5A and B).
3.2.6. DNA fragmentation assay. Fragmentation of DNA by
activated endonucleases inside the cell at the onset of drug
treatment is one of the markers for apoptosis.41 Therefore, we
investigated the possibility of DNA fragmentation in REH cells
aer 48 h of treatment with 5t (0, 0.1, 0.5 and 1 mM).Fig. 4 Measurement of mitochondrial membrane potential. Total mitoc
using JC-1 dye. REH cells were treated with 5t (0, 0.1 and 0.5 mM) for 48
analyzed in ﬂow cytometer. 2,4-DNP treated cells were used as a positiv
and JC-1 stained DMSO treated cells served as control. A. Dot plot show
(high MMP) and green (low MMP) ﬂuorescence ratio of JC-1 with error
45498 | RSC Adv., 2015, 5, 45492–45501Interestingly, the treatment of 5t resulted in a fragmented DNA
ladder formation in a concentration-dependent manner from
0.5 mM onwards, which suggested possible apoptotic induction
upon 5t treatment (Fig. 6A). Both DNA fragmentation and
Annexin-V-FITC staining conrmed the induction of apoptosis
in REH cells aer the treatment with 5t.
3.2.7. Eﬀect of 5t on intracellular ROS production. Gener-
ation of reactive oxygen species by inducing cell death or
apoptosis is one of the mechanisms of action of many drugs. To
examine the generation of ROS, REH cells were treated with 5t
(0.5 mM) at diﬀerent time points such as 5, 15, 30 and 60hondrial membrane potential after treatment with 5t was measured by
h. Cells were harvested, stained with JC-1 dye at 37 C for 20 min and
e control, negative control is DMSO treated cells without JC-1 staining
ing control as well as 5t treated REH cells. B. Bar diagram showing red
bars.
This journal is © The Royal Society of Chemistry 2015
Fig. 5 Annexin V-FITC ﬂow cytometry. Apoptotic signals from 5t treated REH cells was detected using Annexin V-FITC staining. After 48 h of
treatment with 5t (0, 0.1 and 0.5 mM) cells were harvested, and stained with both Annexin V-FITC and propidium iodide for 20 minutes and
analyzed in ﬂow cytometer. DMSO treated cells were used as vehicle control. A. Dot plot representing control and 5t treated cells. B. Bar diagram
representing early apoptotic, late apoptotic and necrotic population of control as well as treated cells. Experiment was repeated minimum two
times and error bar was represented.
Fig. 6 Detection of DNA fragmentation and ROS generation in 5t treated REH cells. A. REH cells were treated with 5t (0, 0.1, 0.5 and 1 mM for 48
h) and cells were harvested, genomic DNA was isolated and subjected to agarose gel electrophoresis. DMSO treated cells were used as vehicle
control. Samples were run on a 2% agarose gel (50 v for 3 h) along with the DNAmarker. ‘C’ represents the DMSO treated samples, ‘M’ represents
the DNA marker lane. B. REH cells were seeded (0.5  105 cells per ml) and treated with 0.5 mM of 5t for diﬀerent time points (5, 15, 30 and 60
min). Cells were harvested and stained with 0.5 mM H2DCFDA for 15 min at 37 C. ROS production was analyzed using ﬂow cytometer. Positive
control indicates H2O2 treated cells. Cells without H2DCFDA served as a negative control and DMSO treated cells with H2DCFDA was served as
control. % cells which are positive for green ﬂuorescent of ROS were measured.
Paper RSC Advancesminutes. Cells treated with H2O2 served as a positive control.
The results showed no ROS generation by 5t at the selected time
points (Fig. 6B), which suggested 5t induced cell death is
independent of ROS production.This journal is © The Royal Society of Chemistry 20154. Conclusion
In summary, a series of 25 isatin-hydrazone derivatives with
various structural features were synthesized and theirRSC Adv., 2015, 5, 45492–45501 | 45499
RSC Advances Papercytotoxicity was evaluated against human cervix carcinoma, T-
lymphocyte and murine leukemia cell lines. The structure
activity relationship studies indicated that a methyl group on
the isatin and a 3,4,5-trimethoxy substituents on the benzene
are required for pronounced cytotoxicity (5s, 5q and 5t).
Therefore, derivative 5t was selected for further studies to
understand the mechanism of action in two diﬀerent leukemic
cell lines, REH and K562. The cell cycle study, analysis of
mitochondrial membrane potential and Annexin V-FITC using
ow cytometry suggested that 5t was able to induce apoptosis
without arresting the cell cycle. In summary, 5t, compound with
potent anticancer activity could be studied further and devel-
oped as an anticancer agent.
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